Table 5. Multivariate linear regression analyses for the estimated risk of high OGTT glucose levels.
| Parameters | Unstandardized coefficient (95% CI) | Standardized coefficient (β) | P | |
|---|---|---|---|---|
| Methylation at Pos. 1 | 42.23 | (31.90 to 52.57) | 0.539 | <0.001*** |
| Age | 0.23 | (−0.49 to 0.96) | 0.044 | 0.523 |
| Sex | −18.38 | (−44.80 to 8.11) | −0.105 | 0.173 |
| BMI | 1.26 | (−1.54 to 4.05) | 0.060 | 0.376 |
| Smoking | −3.491 | (−25.21 to 18.23) | −0.024 | 0.751 |
| Methylation at Pos. 2 | 31.74 | (26.23 to 37.25) | 0.673 | <0.001*** |
| Age | 0.09 | (−0.55 to 0.72) | 0.016 | 0.792 |
| Sex | −15.49 | (−38.79 to 7.81) | −0.088 | 0.191 |
| BMI | 0.50 | (−1.97 to 2.97) | 0.024 | 0.688 |
| Smoking | −6.39 | (−25.54 to 12.74) | −0.045 | 0.510 |
| Methylation at Pos. 3 | 42.47 | (33.03 to 51.91) | 0.582 | <0.001*** |
| Age | 0.35 | (−0.35 to 1.05) | 0.065 | 0.326 |
| Sex | −12.37 | (−38.19 to 13.44) | −0.071 | 0.345 |
| BMI | 0.83 | (−1.89 to 3.56) | 0.040 | 0.546 |
| Smoking | −2.60 | (−23.68 to 18.47) | −0.018 | 0.807 |
| Methylation at Pos. 4 | 42.64 | (31.44 to 53.84) | 0.519 | <0.001*** |
| Age | 0.24 | (−0.50 to 0.93) | 0.045 | 0.522 |
| Sex | −18.17 | (−45.17 to 8.84) | −0.104 | 0.186 |
| BMI | 0.90 | (−1.97 to 3.77) | 0.043 | 0.536 |
| Smoking | −8.25 | (−30.44 to 53.84) | −0.058 | 0.464 |
| Methylation at Pos. 5 | 37.08 | (28.06 to 46.09) | 0.546 | <0.001*** |
| Age | 0.06 | (−0.67 to 0.78) | 0.011 | 0.873 |
| Sex | −21.25 | (−47.59 to 5.08) | −0.121 | 0.113 |
| BMI | 1.00 | (−1.80 to 3.80) | 0.048 | 0.480 |
| Smoking | −10.82 | (−32.58 to 10.95) | −0.076 | 0.328 |
| Methylation at Pos. 7 | 43.42 | (32.82 to 54.01) | 0.535 | <0.001*** |
| Age | 0.28 | (−0.45 to 1.00) | 0.051 | 0.453 |
| Sex | −20.89 | (−47.27 to 5.48) | −0.119 | 0.120 |
| BMI | 1.74 | (−1.04 to 4.52) | 0.083 | 0.217 |
| Smoking | −5.52 | (−27.23 to 16.19) | −0.039 | 0.616 |
| Methylation at Pos. 8 | 30.02 | (23.40 to 36.64) | 0.580 | <0.001*** |
| Age | 0.25 | (−0.45 to 0.95) | 0.047 | 0.477 |
| Sex | −22.50 | (−47.99 to 3.00) | −0.128 | 0.083 |
| BMI | 0.99 | (−1.72 to 3.70) | 0.047 | 0.472 |
| Smoking | −10.02 | (−31.50 to 10.64) | −0.073 | 0.330 |
| Methylation at Pos. 9 | 25.42 | (21.04 to 29.79) | 0.672 | <0.001*** |
| Age | 0.09 | (−0.55 to 0.72) | 0.016 | 0.787 |
| Sex | −18.28 | (−41.43 to 4.88) | −0.104 | 0.121 |
| BMI | 0.74 | (−1.71 to 3.19) | 0.035 | 0.551 |
| Smoking | −6.60 | (−25.66 to 12.47) | −0.046 | 0.495 |
| Methylation at Pos. 10 | 28.27 | (20.61 to 35.93) | 0.498 | <0.001*** |
| Age | 0.41 | (−0.33 to 1.16) | 0.077 | 0.276 |
| Sex | −25.53 | (−52.60 to 1.53) | −0.146 | 0.064 |
| BMI | 1.47 | (−1.40 to 4.34) | 0.070 | 0.312 |
| Smoking | −7.97 | (−30.34 to 14.40) | −0.056 | 0.483 |
The methylation frequencies from Figure 2C and clinical results from all individuals (49 NGT and 114 T2D patients) were analyzed using multivariate linear regression analyses. Data are presented as standardized regression coefficient, β, and unstandardized coefficient, B (95% CI). BMI, body mass index. *, P value < 0.05; **, P value < 0.01; ***, P value < 0.001.